We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Even in the midst of the COVID-19 pandemic, some drugmakers have continued to impose price hikes, raising the list prices for 42 branded drugs by an average of 3.5 percent in July so far, according to a drug price watchdog. Read More
Moderna has tapped Spanish pharma company Laboratorios Farmacéuticos Rovi to conduct large-scale, commercial fill-finish manufacturing of its COVID-19 vaccine candidate in order to bolster international supply. Read More
The federal government has granted two contracts worth more than $2 billion as part of Operation Warp Speed — $1.6 billion to Novavax to manufacture and develop its COVID-19 vaccine candidate, and $450 million to Regeneron Pharmaceuticals to manufacture and supply its antibody cocktail to treat COVID-19. Read More
Emergent BioSolutions has secured a five-year agreement with Johnson and Johnson to manufacture drug substances for J&J’s COVID-19 vaccine candidate. Read More
The Department of Justice (DOJ) has charged Indian drugmaker Glenmark Pharmaceuticals with allegedly conspiring to increase prices on the cholesterol drug pravastin. Read More
Japanese drugmaker Fujifilm is partnering with India’s Dr. Reddy’s and Dubai-based Global Response Aid (GRA) to manufacture and sell its influenza drug Avigan (favipiravir) for the treatment of COVID-19. Read More
After weeks of waiting, Gilead Sciences announced yesterday that it will charge U.S. insurers $3,120 for a six-vial, five-day course of remdesivir, and a lower price of $2,340 for governments of developed countries, including the U.S. Read More